Perrenoud G, Messerli F, Thierry A-C, Beltraminelli N, Cousin P, Fasel N, Vallet V, Demotz S, Duchosal M A, Moulon C
Dictagene, 4, chemin de la Vuliette, CH-1000 Lausanne 25, Switzerland.
Vaccine. 2004 Dec 9;23(4):480-8. doi: 10.1016/j.vaccine.2004.06.030.
A recombinant rubella virus E1 (rE1) glycoprotein was produced and some of its chemical and immunological features were characterized. Two animal models were then used to establish that the rE1 glycoprotein and rubella virus particles shared antigenic and immunogenic properties. In the first one, sera from rE1 glycoprotein-immunized BALB/c mice neutralized in vitro rubella virus infection. In the second model, severe combined immune deficient (SCID) mice implanted with tonsil fragments from rubella immune donors and immunized with rE1 glycoprotein produced human anti-rubella virus antibodies. Altogether, these results showed that immunization with rE1 glycoprotein elicited neutralizing anti-rubella virus antibodies. This study thus indicated that the rE1 glycoprotein could constitute a non-replicating rubella vaccine.
制备了一种重组风疹病毒E1（rE1）糖蛋白，并对其一些化学和免疫学特性进行了表征。然后使用两种动物模型来证实rE1糖蛋白和风疹病毒颗粒具有共同的抗原性和免疫原性。在第一个模型中，来自用rE1糖蛋白免疫的BALB/c小鼠的血清在体外中和了风疹病毒感染。在第二个模型中，植入来自风疹免疫供体的扁桃体片段并用rE1糖蛋白免疫的严重联合免疫缺陷（SCID）小鼠产生了人抗风疹病毒抗体。总之，这些结果表明用rE1糖蛋白免疫可引发中和性抗风疹病毒抗体。因此，这项研究表明rE1糖蛋白可构成一种非复制性风疹疫苗。
